Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2017
At a glance
- Drugs Edaravone (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 05 Dec 2017 According to a Mitsubishi Tanabe Pharma America media release, post-hoc study results will be presented at the 28th International Symposium on ALS/MND in Boston.
- 05 Dec 2017 According to a Mitsubishi Tanabe Pharma America media release, company announced that the data from this study will be presented at the 28th International Symposium on ALS/MND in Boston.
- 01 Jul 2017 Results of post-hoc analysis assessing efficacy and safety, published in the Lancet Neurology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History